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Abstract 
  Cognitive decline in Parkinson's disease (PD) has been observed in the domains of visuospatial 
capacity, memory and frontal lobe functions. The contributions of dopaminergic system to 
cognitive dysfunction in PD and the cognitive effect of dopamine agonist receptor remain 
controversial.  The aim of this study was evaluate the influence on a non-ergot dopamine receptor 
agonist pramipexole on cognitive functions in PD patients. Two groups of patients with idiopathic 
PD (8 patients in each group) were investigated during one year of treatment. The patients 
involved in the study were selected according to dopamine agonist medication. While all patients 
were on levodopa and selegiline treatment only one group of patients (8 patients) received 
dopamine agonist pramipexole (as Mirapexin) 3-4 mg/day. Two groups did not differ for the 
gender ratio, age, disease duration and years of education.  Cognitive testing was performed in all 
patients using Verbal Fluency Test (VFT, category and letter fluency) and Hooper Visual 
Organization Test (HVOT) to assess frontal lobe functions, including attention and integrate 
function.  Both groups of PD patients demonstrated significant cognitive decline compared to 
controls (p<0.05) according to visuospatial capacity and executive function. Semantic fluency was 
slightly better in pramipexole group but did not reach significance (p<0.05).  In conclusion we can 
say the further studies are needed with bigger number of patients included to explore the influence 
of dopaminergic medication on cognitive function in Parkinson’s disease. 
Key words: Parkinson’s disease, cognitive functions, dopamine agonists, pramipexole, verbal and 
category fluency, The Hooper Visual Organization Test  
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Introduction 
Parkinson’s disease (PD) has long been conceived to be mainly a motor disorder. In the last few 
decades it has been increasingly more recognized that many patients with PD will experience 
cognitive decline in the course of their illness (1). Cognitive impairment in PD patients typically 
involves executive functions (defined as planning and performance of goal-directed behaviour and 
measured by tests assessing abilities such as planning, set shifting, set maintenance), attention and 
visuo-spatial functions (2). The mechanisms underlying cognitive impairment in PD probably 
involve impaired activity in fronto-striatal pathways subserving cognitive functions (3). Current 
age, age of onset and disease duration exert important effects on cognitive functions in PD patients 
(4). The effect of antiparkinsonian medication on cognitive performance is another confounding 
factor. Dopamine  (DA) agonists have shown beneficial therapeutic effects on motor symptoms in 
PD, but their influence on cognitive functions is still controversial. Some studies suggest that DA 
ameliorates a certain frontal lobe function, such as focused attention (5), but other failed to 
demonstrate cognitive improving in patients treated with a DA agonist (6). In fact, the effects of 
levodopa and DA on cognitive functions have been reported as beneficial as well as deleterious 
(7). Pramipexole is a novel non-ergoline dopamine agonist with high binding specificity for the 
dopamine D2 receptor family and with preferential affinity to the dopamine D3 receptor subgroup 
(8). Clinical trials with pramipexole as monotherapy and as an adjunct to levodopa have shown the 
compound to be safe, well tolerated, and efficacious (9). However the recent study form Brusa et al 
(10) indicates that pramipexole slightly worsens cognitive function in PD patients compared to an 
off-treatment condition. The negative influence on cognition was explained by unbalanced 
stimulation of D2-receptor subtypes alone by pramipexole. The aim of this study is to evaluate the 
influence of the DA agonist   pramipexole on cognitive functions in PD patients already treated 
with levodopa. 
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Material and   Methods 
Subjects 
Sixteen patients referred to the Movement Disorders and Clinical Neuropharmacological Centre, 
Neurological Department, Zagreb School of Medicine, was investigated during one year of 
treatment.  All subjects fulfilled the UK Parkinson's Disease Society Brain Bank clinical criteria 
for PD (11).  An exclusion criterion was clinical evidence of possible dementia assessed using the 
mini mental state examination (MMS). Only patients scoring above 24 on the MMS were included 
in the study. The patients with idiopathic PD were divided into two groups of 8 patients each, 
according to DA agonist medication. While all the patients received levodopa and selegiline, one 
group (8 patients) has been additionally treated with the DA agonist pramipexole (Table 1).   
Eight control subjects (four female and four male), matched for age (mean age 56.3 ± 9.3, range 
40-66) and educational level (mean years 12.5 ± 2.8, range 8-17), with no history of central 
nervous system disorders, were examined. Controls were also given the MMS with the same 
inclusion threshold as the patients (>24).  The two groups of PD patients and controls did not differ 
for the gender ratio, age and years of education (Table 1).  
All the subjects gave their informed consent to participation in the study and the local research 
ethics committee approved the study. 
 
Neuropsychological assessment 
Neuropsychological testing was performed to assess the frontal lobe functions, including attention 
and integrated functions. Cognitive tests included the Verbal Fluency Test (semantic and letter 
fluency) and the Hooper Visual Organization Test (12,13). Semantic fluency was evaluated by 
asking subjects to generate in one-minute periods as many different items as possible from the 
category of animals. Subjects were provided superordinate categories.   In letter fluency, subjects 
 7 
were instructed to generate words starting with a specific letter of the alphabet (FAS). They were 
instructed that proper nouns and words with the same stem but different endings would not be 
counted.  The score was the number of different words produced in one minute.  
On the Hooper Visual Organization Test subjects recognized cut up and rearranged pictures of 30 
common objects.   
Statistical analysis 
The effect of levodopa alone, levodopa and DA agonist pramipexole on cognitive functions was 
assessed by means of one-way ANOVA. Post hoc comparisons were performed by Scheffe test. 
Accepted significance level was p<0.05.  
The software package Statistica v. 5.5 was used for statistical analysis.  
 
Results 
The scores on the tasks are reported in Table 2. A one-way ANOVA showed a significant effect 
for group regarding verbal fluency (F=13.64, p<0.001), semantic fluency (F=3.92, p<0.05) and the 
Hooper Visual Organization Test (F=18.98, p<0.001). Post hoc analysis (Scheffe test) 
demonstrated that PD patients performed worse on verbal fluency, semantic fluency and the 
Hooper Visual Organization Test (p<0.05) compared to age and educational matched controls. 
However there was no difference between PD patients treated with levodopa alone or levodopa 
combined with pramipexole (Scheffe test, p<0.05). 
In semantic categories tasks provided with superordinate categories there was no difference in 
cognitive performance of PD patients compared to the controls (Table 2). Semantic fluency was 
slightly better in pramipexole group, but did not reach statistical significance (post hoc analysis, 
Scheffe test, p>0.05).  
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Discussion 
Executive function deficits are among the most prominent cognitive deficits in PD, and may be one 
of the earliest signs of cognitive deterioration in the disorder (14). Regarding these fact we wonted 
to explore the influence of DA agonist pramipexole on executive function in PD patients. 
 Letter and category fluency tests were originally developed to assess fluency in aphasic patients, 
but impaired verbal fluency could be also a sign of executive dysfunction. To generate words in 
these tasks, subject must plan and initiate a systematic search of memory (15). Performance in 
letter fluency test is reported both as intact (16) and impaired in PD patients (17). Compared to 
controls, our PD patients showed significantly inferior performance in this task. In trials calling for 
semantic category, the patients did not differ from controls. They were provided with 
superordinate categories to assist retrieval, and maybe this is the reason for the intact category 
fluency in PD patients. More explicit instructions could have beneficial effect, because PD patients 
have difficulty in initiating cognitive strategies for retrieving   stored information. Some studies 
reported impairment in category fluency tasks in PD patients and their normalization when more 
explicit instructions were provided (18).  
Our patients were worse in the Hooper Visual Organization Test compared to the controls. The 
Hooper Visual Organization Test is a measure of visuospatial processing commonly employed in 
neuropsychological assessment. Huntington’s disease patients demonstrate early in the course of 
the disease impairment on The Hooper Visual Organization Test, and actually their performance 
was highly discriminative of early symptomatic patients from asymptomatic gene carriers (19). 
Huntington’s disease is characterised by striatal pathology and patients early in the course of the 
disease demonstrate specifically cognitive impairment caused by frontostriatal dysfunction (20).  
On the other hand The Hooper Visual Organization Test is a measure of visual integration ability, 
but also requires elementary vocabulary skills and the ability to label common objects. Diminished 
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performance in this test may be due to difficulty to name the objects or to impaired visual 
organization. Verbal disturbances, primarily associated with word finding, are common in PD 
patients (21).    
Although PD patients treated with pramipexole had a higher Hoehn and Yahr stage than those 
treated with levodopa, there was no difference in cognitive performance. The benefit of levodopa 
treatment on cognition is usually less pronounced than that on motor symptoms (22). Some 
specific cognitive deficits may recover whereas others remain unimproved (23). Our results 
indicate dissociation of specific cognitive functions and motor symptoms in PD. This is consistent 
with the view that most cognitive functions in PD are more dependent on nondopaminergic 
mechanisms than the motor symptoms (24). 
There was no significant effect of the DA agonist pramipexole on cognitive test performance in PD 
patients compared to levodopa, despite their different mode and site of therapeutic actions. Recent 
study from Brusa et al (25) demonstrates that pramipexole slightly worsens cognitive function in 
PD patients compared to an off-treatment, contrary to effect exerted by levodopa and DA agonist 
pergolide.  These results were explained by D1 and D2-receptors stimulation produced by 
levodopa and pergolide, contrary to stimulation of D2 and D3 exerted by pramipexole. These 
findings suggest that D1-receptor stimulation is necessary to spare or recover cognitive function in 
PD patients. Other reason for cognitive decline in patients treated by pramipexole was explained as 
D3-receptors stimulation, which is thought to produce attentional deficit. Our results did not show 
cognitive differences between PD patients treated with pramipexole or levodopa alone. However 
we did not compare a treatment effect regarding the wash out condition or monotherapy with 
pramipexole on cognitive functions. Our results suggest that pramipexole in combination with 
levodopa does not produce cognitive dysfunction in mild/moderate PD patients. A limitation of our 
study is a small sample of control and PD patients. Subjects took pramipexole for no more than 
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one year. This duration is a relatively short period of treatment, and chronic treatment with the DA 
agonists is needed to further elicit the influence of DA pramipexole and levodopa on cognitive 
function in PD patients. 
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Table 1. Patient data 
 
 
 
 
PARKINSON’S DISEASE  
LEVODOPA 
TREATMENT 
PRAMIPEXOLE 
TREATMENT 
CONTROLS 
Number of patients 8 8 8 
Female/Male 4/4 3/5 4/4 
Mean age (SD), 
range 
56.1 (7.5), 43-63 years 55.8 (6.7), 41-63 years 56.3 (9.3), 40-66 years 
Years of education   
(SD), range 
11.9 (4.3), 7-15 years 12.3 (4.4), 8-17 years 12.5 (2.8), 8-17 years 
Hoehn and Yahr 
stage 
2.5 3  
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Table 2. Neuropsychological performance of the patients with Parkinson’s disease treated with 
levodopa or DA agonist pramipexole and of the control group 
 
 
PARKINSON’S DISEASE  
LEVODOPA 
TREATMENT  
PRAMIPEXOLE 
TREATMENT 
CONTROLS 
Letter fluency, mean (SD) 26.1 (5.9)* 27.4 (5.5)* 31.4 (5.3) 
Semantic fluency, mean (SD)  17.1* (4.7) 18.2 *(9) 20.5 (5.4) 
Hooper Visual Organization 
Test, mean (SD) 
17.1(3.8)* 17.8 (7.1)* 22.6 (6.2) 
Semantic fluency provided 
with superordinate categories, 
mean (SD) 
15.5 (5.9) 16.1 (5.5) 16.7(5.3) 
  
 
 
* One-way ANOVA,  post hoc Scheffe Test, p<0.05 
